Journal
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 61, Issue 6, Pages 971-976Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2008.08.033
Keywords
-
Categories
Funding
- Barrier Therapeutics, Inc
Ask authors/readers for more resources
Background: Pramiconazole is a broad-spectrum triazole antifungal with potential for oral treatment of pityriasis versicolor. Objective: We sought to assess the efficacy and tolerability of 5 doses of pramiconazole relative to placebo. Methods: This was a randomized, multicenter, double-blind, placebo-controlled, 28-day, close-finding study. A total of 147 patients were randomized to treatment with placebo or one of 5 closes of pramiconazole; treatment lasted for 3 consecutive days. Efficacy was based on mycological response, severity of clinical signs and symptoms, and the Investigator Global Assessment of lesion clearance. Results: A statistically significant (P < .001) dose-dependent effect was observed. When compared with placebo, a significant response (P < .05) was obtained for all but the lowest single close of pramiconazole. There were no serious, treatment-related adverse events or other safety concerns. Limitations: The follow-Lip period was limited to 1 month after treatment onset. Conclusions: Pramiconazole is a well-tolerated and effective treatment for pityriasis versicolor and the most effective treatment regimen in this study included 200 or 400 mg taken once, 200 mg taken once daily for 2 or 3 days. (J Am Acad Dermatol 2009;61:971-6.)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available